Literature DB >> 18514927

A global ranking approach to end points in trials of mechanical circulatory support devices.

G Michael Felker1, Kevin J Anstrom, Joseph G Rogers.   

Abstract

BACKGROUND: Although previous studies of mechanical circulatory support devices (MCSDs) have used all-cause mortality as a primary end point, trends in device technology and implementation will increasingly necessitate the use of composite end points for MCSD studies. The ideal composite end point for studies of MCSDs is uncertain. METHODS AND
RESULTS: We reviewed the advantages and disadvantages of traditional composite end points in MCSD studies from both a clinical and statistical perspective. Although composite end points may increase statistical power, they also introduce potential problems in interpretation of data, and in some situations may interpret a given clinical course in ways very different than it would be viewed by patients or providers. A global ranking end point, which ranks various aspects of the clinical course based on a prespecified hierarchical ranking system, may provide many of the advantages of composite end points while avoiding many of the pitfalls. One version of such an end point for use in MCSD studies is proposed.
CONCLUSIONS: Use of a global ranking end point for incorporating various components of the clinical course into a single end point retains much of the benefit of composite end points while avoiding many of the limitations associated with the use of composites. Adoption of such end points may facilitate the development of MCSD therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18514927     DOI: 10.1016/j.cardfail.2008.01.009

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  15 in total

1.  Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease.

Authors:  Kevin D Hill; H Scott Baldwin; David P Bichel; Alicia M Ellis; Eric M Graham; Christoph P Hornik; Jeffrey P Jacobs; Robert D B Jaquiss; Marshall L Jacobs; Prince J Kannankeril; Jennifer S Li; Rachel Torok; Joseph W Turek; Sean M O'Brien
Journal:  Am Heart J       Date:  2020-05-20       Impact factor: 4.749

2.  Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations.

Authors:  Roland A Matsouaka; Rebecca A Betensky
Journal:  Stat Med       Date:  2014-11-13       Impact factor: 2.373

Review 3.  Drugs' development in acute heart failure: what went wrong?

Authors:  Vincenzo Teneggi; Nithy Sivakumar; Deborah Chen; Alex Matter
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

4.  An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.

Authors:  Roland A Matsouaka; Aneesh B Singhal; Rebecca A Betensky
Journal:  Stat Methods Med Res       Date:  2016-12-29       Impact factor: 3.021

5.  Alive and Ventilator Free: A Hierarchical, Composite Outcome for Clinical Trials in the Acute Respiratory Distress Syndrome.

Authors:  Victor Novack; Jeremy R Beitler; Maayan Yitshak-Sade; B Taylor Thompson; David A Schoenfeld; Gordon Rubenfeld; Daniel Talmor; Samuel M Brown
Journal:  Crit Care Med       Date:  2020-02       Impact factor: 7.598

Review 6.  Are all outcomes in chronic heart failure rated equally? An argument for a patient-centred approach to outcome assessment.

Authors:  Sungwon Chang; Phillip J Newton; Sally Inglis; Tim Luckett; Henry Krum; Peter Macdonald; Patricia M Davidson
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

Review 7.  End points for comparative effectiveness research in heart failure.

Authors:  Larry A Allen; John A Spertus
Journal:  Heart Fail Clin       Date:  2012-10-18       Impact factor: 3.179

8.  Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF.

Authors:  Beth A Davison; Gad Cotter; Hengrui Sun; Li Chen; John R Teerlink; Marco Metra; G Michael Felker; Adriaan A Voors; Piotr Ponikowski; Gerasimos Filippatos; Barry Greenberg; Sam L Teichman; Elaine Unemori; Gary G Koch
Journal:  Clin Res Cardiol       Date:  2011-03-17       Impact factor: 5.460

9.  Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia.

Authors:  Sumeet Subherwal; Kevin J Anstrom; William S Jones; Michael G Felker; Sanjay Misra; Michael S Conte; William R Hiatt; Manesh R Patel
Journal:  Am Heart J       Date:  2012-09       Impact factor: 4.749

10.  Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries.

Authors:  Adrian F Hernandez; Alisa M Shea; Carmelo A Milano; Joseph G Rogers; Bradley G Hammill; Christopher M O'Connor; Kevin A Schulman; Eric D Peterson; Lesley H Curtis
Journal:  JAMA       Date:  2008-11-26       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.